Finance

Beta
Lists
SGMT:NASDAQ
Sagimet Biosciences Inc
$7.61
+2.01%
(+0.15) 1D
$7.61
-0.01% (-0.00050)
After hours
Closed: Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
$7.54
High
$7.69
Low
$7.41
Mkt. cap
469.93M
Avg. vol.
1.20M
Volume
834.22K
52-wk high
$11.41
52-wk low
$4.50
EPS
-$1.34
Shares outstanding
61.18M
No. of employees
16
Open
$7.54
High
$7.69
Low
$7.41
Mkt. cap
469.93M
Avg. vol.
1.20M
Volume
834.22K
52-wk high
$11.41
52-wk low
$4.50
EPS
-$1.34
Shares outstanding
61.18M
No. of employees
16
News stories
From sources across the web
About Sagimet Biosciences Inc
CEO-
Employees16
Founded2006
HeadquartersSan Mateo, California, United States
SectorBiotechnology
Analyst ratings
Based on 9 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current $7.61
$49.00 (+543.89%)
Average
$28.44 (+273.72%)
Lowest
$12.00 (+57.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$31.00
+307.4%
07/01/2026
Yun Zhong
Wedbush
Buy
Maintained
$28.00
+267.9%
06/22/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$29.00
+281.1%
05/26/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$12.00
+57.7%
05/19/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$28.00
+267.9%
05/13/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$49.00
+543.9%
05/12/2026
Ritu Baral
TD Cowen
Buy
Maintained
$21.00
+176%
05/12/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$33.00
+333.6%
05/01/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$25.00
+228.5%
04/29/2026
Eliana Merle
Barclays
Hold
Maintained
$8.00
+5.1%
04/02/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
$28.00
+267.9%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$28.00
+267.9%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.25M
9.73M
6.73M
7.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.68M
4.60M
4.03M
4.72M
Operating expense
11.92M
14.33M
10.76M
11.71M
Total operating expenses
11.92M
14.33M
10.76M
11.71M
Operating income
-11.92M
-14.33M
-10.76M
-11.71M
Other non operating income
-
-
-
-
EBT including unusual items
-10.39M
-12.91M
-9.57M
-10.65M
EBT excluding unusual items
-10.39M
-12.91M
-9.57M
-10.65M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.39M
-12.91M
-9.57M
-10.65M
Net profit margin
-
-
-
-
Earnings per share
-0.32
-0.40
-0.29
-0.33
Interest and investment income
1.54M
1.43M
1.20M
1.06M
Interest expense
-
-
-
-
Net interest expenses
1.54M
1.43M
1.20M
1.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more